Underuse of Anticoagulation in Older Patients with Atrial Fibrillation and CHADS(2) Score ae 2: Are We Doing Better Since the Marketing of Direct Oral Anticoagulants?

Henrard Severine; Vandenabeele Caroline; Marien Sophie; Boland Benoit; Dalleur Olivia

首页> 外文期刊>Drugs and aging >Underuse of Anticoagulation in Older Patients with Atrial Fibrillation and CHADS(2) Score ae 2: Are We Doing Better Since the Marketing of Direct Oral Anticoagulants?

【24h】

Underuse of Anticoagulation in Older Patients with Atrial Fibrillation and CHADS(2) Score ae 2: Are We Doing Better Since the Marketing of Direct Oral Anticoagulants?

机译：在高龄患者和乍得（2）评分AE 2中的老年患者的抗凝剂（2）评分AE 2：从直接口服抗凝剂的营销以来我们做得更好吗？

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Our objectives were to (1) describe the evolution of the underuse of anticoagulants in older people with atrial fibrillation (AF) and a CHADS(2) score >= 2 since direct oral anticoagulants (DOACs) were introduced to the market and (2) describe factors associated with this underuse.

机译：我们的目标是（1）描述了老年人抗凝剂的抗凝血剂的进化，因为直接口服抗凝血剂（Doacs）被引入市场和（2）描述与此欠利用相关的因素。

著录项

来源
《Drugs and aging》 |2017年第11期|共10页
作者
Henrard Severine; Vandenabeele Caroline; Marien Sophie; Boland Benoit; Dalleur Olivia;
展开▼
作者单位

Catholic Univ Louvain Louvain Drug Res Inst Clin Pharm Res Grp Brussels Belgium;

Clin Univ St Luc Pharm Brussels Belgium;

Catholic Univ Louvain Louvain Drug Res Inst Clin Pharm Res Grp Brussels Belgium;

Catholic Univ Louvain Inst Hlth &

Soc IRSS Brussels Belgium;

Catholic Univ Louvain Louvain Drug Res Inst Clin Pharm Res Grp Brussels Belgium;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
专利

1. Underuse of Anticoagulation in Older Patients with Atrial Fibrillation and CHADS(2) Score ae 2: Are We Doing Better Since the Marketing of Direct Oral Anticoagulants? [J] . Henrard Severine, Vandenabeele Caroline, Marien Sophie, Drugs and aging . 2017,第11期

机译：在高龄患者和乍得（2）评分AE 2中的老年患者的抗凝剂（2）评分AE 2：从直接口服抗凝剂的营销以来我们做得更好吗？
2. Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts" [J] . Piccini Jonathan P., Stevens Susanna R., Chang YuChiao, Circulation: An Official Journal of the American Heart Association . 2013,第11期

机译：对有关“非瓣膜性房颤患者中风和全身性栓塞的预测指标：肾功能不全：ROCKET AF（Rivaroxaban每日一次，口服，直接因素）中的R（2）CHADS（2）指数的验证的答复Xa抑制与维生素K拮抗剂在房颤预防卒中和栓塞试验中的比较以及ATRIA（房颤的抗凝和危险因素）研究队列”
3. Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts" [J] . Apostolakis Stavros, Lane Deirdre A., Banerjee Amitava Circulation: An Official Journal of the American Heart Association . 2013,第11期

机译：Acostolakis等人关于文章的信，“肾功能障碍是非衰弱性心房颤动患者中风和全身栓塞的预测因子：验证R（2）牧草（2）指数在火箭AF中的指数（Rivaroxaban曾经每日，口服，与维生素K拮抗剂相比，直接因子XA抑制预防心房颤动中的中风和栓塞试验）和阿里亚（心房颤动的抗凝和危险因素）研究队列“
4. Self-management of Oral Anticoagulants by Patients with Atrial Fibrillation: How Effective and Safe Is It? [C] . R. Cazzin, P. Serra C. Lestuzzi International Workshop on Cardiac Arrhythmias . 2002

机译：心房颤动患者的口腔抗凝血剂自我管理：它有多效益和安全？
5. Switching from Vitamin K Antagonists to Non-vitamin K Oral Anticoagulants, Drug-Drug Interactions, and Health Outcomes among Working-Age Adults with Atrial Fibrillation [D] . Feng, Xue. 2018

机译：从维生素K拮抗剂切换到非维生素K口服抗凝剂，药物 - 药物相互作用，以及具有心房颤动的工作年龄成年人之间的健康状况
6. Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ⩾ 2 [O] . Maria M Fernandez, Jianmin Wang, Xin Ye, 2015

机译：系统评价和网络荟萃分析在非瓣膜性房颤和CHADS2评分⩾2患者中使用依多沙班与其他非维生素K拮抗剂口服抗凝剂的相对疗效和安全性
7. Response to Letter Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS 2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts” [O] . Jonathan P. Piccini, Susanna R. Stevens, YuChiao Chang, 2013

机译：回应关于物品的信，“肾功能障碍是非衰弱性心房颤动患者中风和全身栓塞的预测因子：验证R 2 Chads 2指数在火箭AF中（rivaroxaban曾经每日，口服，直接因子XA抑制相比维生素K对患者预防心房颤动的卒中和栓塞试验的拮抗剂）和Atria（心房颤动的抗凝和危险因素）研究队列“

Underuse of Anticoagulation in Older Patients with Atrial Fibrillation and CHADS(2) Score ae 2: Are We Doing Better Since the Marketing of Direct Oral Anticoagulants?

摘要

著录项

相似文献

相关主题

期刊订阅